- Home
- LEXX vs PULM Comparison
LEXX vs PULM Comparison
Compare LEXX & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEXX
- PULM
- Stock Information
- Founded
- LEXX 2004
- PULM 2003
- Country
- LEXX Canada
- PULM United States
- Employees
- LEXX N/A
- PULM N/A
- Industry
- LEXX Biotechnology: Pharmaceutical Preparations
- PULM Biotechnology: Pharmaceutical Preparations
- Sector
- LEXX Health Care
- PULM Health Care
- Exchange
- LEXX Nasdaq
- PULM Nasdaq
- Market Cap
- LEXX 16.5M
- PULM 18.3M
- IPO Year
- LEXX N/A
- PULM N/A
- Fundamental
- Price
- LEXX $1.30
- PULM $5.19
- Analyst Decision
- LEXX Strong Buy
- PULM
- Analyst Count
- LEXX 1
- PULM 0
- Target Price
- LEXX $4.00
- PULM N/A
- AVG Volume (30 Days)
- LEXX 193.3K
- PULM 9.7K
- Earning Date
- LEXX 07-14-2025
- PULM 11-07-2025
- Dividend Yield
- LEXX N/A
- PULM N/A
- EPS Growth
- LEXX N/A
- PULM N/A
- EPS
- LEXX N/A
- PULM N/A
- Revenue
- LEXX $615,923.00
- PULM $369,000.00
- Revenue This Year
- LEXX $46.98
- PULM N/A
- Revenue Next Year
- LEXX $17.26
- PULM $134.88
- P/E Ratio
- LEXX N/A
- PULM N/A
- Revenue Growth
- LEXX 49.85
- PULM N/A
- 52 Week Low
- LEXX $0.77
- PULM $1.78
- 52 Week High
- LEXX $3.47
- PULM $10.40
- Technical
- Relative Strength Index (RSI)
- LEXX 76.03
- PULM 54.81
- Support Level
- LEXX $0.98
- PULM $4.70
- Resistance Level
- LEXX $1.34
- PULM $4.87
- Average True Range (ATR)
- LEXX 0.09
- PULM 0.12
- MACD
- LEXX 0.04
- PULM 0.09
- Stochastic Oscillator
- LEXX 91.72
- PULM 100.00
About LEXX Lexaria Bioscience Corp.
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).